Physician profile
Veronica Cieszynski
NPI 1396007597
$1,327.15
in general payments reported to CMS, 2019-2025
16 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $304 · 2023: $443 · 2024: $358 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $215.03 | 2022-2025 | |
| Abbott Laboratories | $162.77 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $154.87 | 2024-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $143.64 | 2022 | |
| Novo Nordisk INC | $140.49 | 2022-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $118.78 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.93 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $69.36 | 2023-2024 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $45.50 | 2023 | Quviviq |
| Seqirus USA INC | $45.24 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Astellas Pharma US INC | $36.76 | 2022-2023 | Veozah |
| Tactile Systems Technology INC | $24.24 | 2023 | Flexitouch Plus, Entre Plus |
| Phathom Pharmaceuticals, INC. | $23.69 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.80 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $18.77 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Cieszynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.